Jing-Mei Hsu
Overview
Explore the profile of Jing-Mei Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alhomoud M, Chokr N, Gomez-Arteaga A, Chen Z, Escalon J, Legasto A, et al.
Transplant Cell Ther
. 2023 Feb;
29(5):326.e1-326.e10.
PMID: 36739088
Pulmonary complications constitute a major cause of morbidity and mortality in the post-allogenic hematopoietic stem cell transplantation (alloHSCT) period. Although chest X-ray (CXR) is customarily used for screening, we have...
2.
Yuen C, Hsu J, Van Besien K, Reshef R, Iwamoto F, Haggiagi A, et al.
J Immunother
. 2022 Apr;
45(5):254-262.
PMID: 35404315
Secondary central nervous system lymphoma (SCNSL) is associated with poor prognosis and new therapeutic approaches are needed. The pivotal trial that led to US Food and Drug Administration (FDA) approval...
3.
Schuster S, Tam C, Borchmann P, Worel N, McGuirk J, Holte H, et al.
Lancet Oncol
. 2021 Sep;
22(10):1403-1415.
PMID: 34516954
Background: In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response rate was 52% and the...
4.
Satlin M, Chen L, Douglass C, Hovan M, Davidson E, Soave R, et al.
Clin Infect Dis
. 2021 May;
73(7):1257-1265.
PMID: 33956965
Background: Levofloxacin prophylaxis is recommended to prevent gram-negative bloodstream infections (BSIs) in patients with prolonged chemotherapy-induced neutropenia. However, increasing fluoroquinolone resistance may decrease the effectiveness of this approach. Methods: We...
5.
Orfali N, Jhanwar Y, Koo C, Pasciolla M, Baldo M, Cuvilly E, et al.
Leuk Lymphoma
. 2021 Feb;
62(7):1629-1638.
PMID: 33586581
We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in patients with relapsed/refractory lymphoma and residual disease after salvage therapy. Thirty-four subjects without complete responses...
6.
Chaekal O, Scaradavou A, Frenet E, Albano M, Cushing M, Desai P, et al.
Blood Adv
. 2020 Oct;
4(20):5146-5156.
PMID: 33091124
We conducted a prospective evaluation of cord blood (CB)-derived adoptive cell therapy, after salvage chemotherapy, for patients with advanced myeloid malignancies and poor prognosis. Previously, we reported safety, feasibility, and...
7.
Camacho-Bydume C, Wang T, Sees J, Fernandez-Vina M, Abid M, Askar M, et al.
Transplant Cell Ther
. 2020 Oct;
27(2):142.e1-142.e11.
PMID: 33053450
Maximizing the probability of antigen presentation to T cells through diversity in HLAs can enhance immune responsiveness and translate into improved clinical outcomes, as evidenced by the association of heterozygosity...
8.
Vedvyas Y, McCloskey J, Yang Y, Min I, Fahey T, Zarnegar R, et al.
Sci Rep
. 2020 Jul;
10(1):12733.
PMID: 32719389
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
9.
Vedvyas Y, McCloskey J, Yang Y, Min I, Fahey T, Zarnegar R, et al.
Sci Rep
. 2019 Jul;
9(1):10634.
PMID: 31337787
While the majority of thyroid cancer patients are easily treatable, those with anaplastic or poorly differentiated recurrent thyroid carcinomas have a very poor prognosis with a median survival of less...
10.
Gergis U, Frenet E, Shore T, Mayer S, Phillips A, Hsu J, et al.
Biol Blood Marrow Transplant
. 2018 Nov;
25(3):466-473.
PMID: 30414955
Adoptive immunotherapy has shown efficacy in patients with relapsed/refractory acute myelogenous leukemia (AML). We conducted a prospective evaluation of cord blood (CB)-based adoptive cell therapy following salvage chemotherapy in patients...